Evidence map›Paper›PMID 25885115›Full record

ArticleBMC cancer2015

Screening of exon 11 of BRCA1 gene using the high resolution melting approach for diagnosis in Moroccan breast cancer patients.

Meryam El Khachibi, Brehima Diakite, Khalil Hamzi, Abdallah Badou, Mohamed Amine Senhaji, Amina Bakhchane, Hassan Jouhadi, Abdelhamid Barakat, Abdellatif Benider, Sellama Nadifi

Abstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Prevalence of Clinically Relevant GermlineFrontiers in genetics · 2022
    Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Meryam El KhachibiGenetics and Molecular Pathology Laboratory, Medical school of Casablanca, Casablanca, Morocco. el.khachibi.meryam@gmail.com.
Brehima DiakiteGenetics and Molecular Pathology Laboratory, Medical school of Casablanca, Casablanca, Morocco. br.diakite@yahoo.fr.
Khalil HamziGenetics and Molecular Pathology Laboratory, Medical school of Casablanca, Casablanca, Morocco. Khalilhamzi@gmail.com.
Abdallah BadouGenetics and Molecular Pathology Laboratory, Medical school of Casablanca, Casablanca, Morocco. abdallahbadou@yahoo.com.
Mohamed Amine SenhajiGenetics and Molecular Pathology Laboratory, Medical school of Casablanca, Casablanca, Morocco. m.amine.senhaji@gmail.com.
Amina BakhchaneLaboratoire de Génétique Moléculaire Humaine, Département de la Recherche Scientifique, Institut Pasteur du Maroc, Casablanca, Morocco. amina-bakhchane@yahoo.fr.
Hassan JouhadiDepartment of Oncology, Ibn Rochd University Hospital, Casablanca, Morocco. h.jouhadi@yahoo.fr.
Abdelhamid BarakatLaboratoire de Génétique Moléculaire Humaine, Département de la Recherche Scientifique, Institut Pasteur du Maroc, Casablanca, Morocco. hamidbarakat@pasteur.ma.
Abdellatif BeniderDepartment of Oncology, Ibn Rochd University Hospital, Casablanca, Morocco. beniderabdel@yahoo.fr.
Sellama NadifiGenetics and Molecular Pathology Laboratory, Medical school of Casablanca, Casablanca, Morocco. nadifisel@yahoo.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIdentification of specific mutations in cancer patients may lead to the discovery of genes, which can affect susceptibility and/or prognosis. It has previously been reported that mutations in BRCA1 and BRCA2 genes are linked to breast cancer. Here, we evaluated the use of the High Resolution Melting (HRM) approach to screen for mutations in exon 11 of BRCA1 gene in Moroccan patients.

methodsHRM analysis was used to screen exon 11 from 71 breast cancer patients in order to detect different variants. Conventional Sanger sequencing was used to confirm the presence of possible mutations. Distribution of different SNPs was determined by SNaPshot analysis software.

resultsIn order to assess the efficacy of the HRM approach to screen for mutations, especially in diagnosis, we first used two samples with previously known mutations, "2924delA and 3398delC". Indeed, these previously known sequence variants were detected by the HRM approach and yielded melting curves with atypical shape relative to wild-type control sequences. We then analyzed, 69 samples from breast cancer patients using the HRM method, and were able to detect two samples with atypical curves. Sequencing of the two samples, using the conventional Sanger approach, confirmed the presence of the same SNP (c.2612C > T) in both samples.

conclusionsOur results strongly suggest that the HRM approach represents a reliable and highly sensitive method for mutation scanning, especially in diagnosis.

Indexed as

BRCA1 ProteinBreast NeoplasmsDNA Mutational AnalysisEarly Detection of CancerExonsFemaleHigh-Throughput Nucleotide SequencingHumansMoroccoMutationPolymorphism, Single NucleotideSensitivity and SpecificityBRCA1 ProteinBRCA1 protein, human

Identifiers

PMID25885115
PMCPMC4351675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.